Market - EUON
Health
News
Market
Regulation
Standards
EHS
The table below highlights available market estimates and forecasts for health nanotechnology products. There are high levels of market share and predicted growth in areas such as cancer/clinical oncology (EUR 64 billion in 2019) and synthetic bone and tooth materials (hydroxyapatite, EUR 1 billion in 2019). Other technologies are currently only emerging but are expected to show a very high growth rate to 2019: dendrimers, proteomics, biomarkers and quantum dots for bio-reagents.
The relative proportions of the global market across the sub-sectors considered here (i.e. cancer, cardiovascular disease, infectious diseases and neurodegenerative diseases, data for diabetes being unavailable) are expected to change only gradually from 2012 to 2019. The largest share of sales is related to cancer treatment followed by central nervous system (CNS) products (largely including pharmaceuticals targeting neurodegenerative diseases) and products to prevent and counter infection (‘anti-infectives’). The global market for nano-pharmaceuticals is growing at a faster pace that the overall market for pharmaceuticals.
|
2014 |
2019 |
USD CAGR [2] |
Source |
|
|---|---|---|---|---|
|
Global |
EUR (billion) |
EUR (billion) |
% |
|
|
Total nanomedicine |
186 |
498 |
16 |
BCC [1] |
|
Total healthcare |
73 |
184 |
12 |
GVR [3] |
|
Total nano-diagnostics |
29 |
109 |
24 |
BCC [1] |
|
Total nano-pharmaceuticals |
157 |
388 |
14 |
BCC [1] |
|
Sub-sectors |
EUR (billion) |
EUR (billion) |
% |
|
|
Cancer |
24.1 |
-- |
-- |
F&S [4] |
|
Clinical oncology |
64.4 |
12 |
GVR [5] |
|
|
Cardiovascular |
5.3 |
-- |
-- |
F&S [4] |
|
Diabetes |
5.0 |
-- |
-- |
F&S [4] |
|
Infectious diseases |
12.8 |
-- |
-- |
F&S [4] |
|
Neurodegenerative diseases |
8.3 |
-- |
-- |
F&S [4] |
|
Applications |
EUR (million) |
EUR (million) |
||
|
Drug delivery |
117 |
201 |
7 |
BCC [1] |
|
QD for biological reagents |
18.6 |
410 |
77 |
BCC [1] |
|
Biomarkers and detection |
70 |
506 |
42 |
BCC [1] |
|
MRI contrast agents (iron) |
9.4 |
14.2 |
5 |
BCC [1] |
|
Surface disinfectants |
-- |
0.9 |
-- |
BCC [1] |
|
Antimicrobial coatings |
56 |
-- |
-- |
VDI [6] |
|
Antibacterial lacquers |
113 |
-- |
-- |
VDI [6] |
|
Nano silver for antimicrobials |
29 |
-- |
-- |
VDI [6] |
|
Proteomics |
-- |
108 |
BCC [1] |
|
|
Hydroxyapatite (bones/teeth) |
264 |
1008 |
26 |
BCC [1] |
|
Dendrimer transfection reagents |
0.7 |
6.6 |
51 |
BCC [1] |
[1] BCC Research (2014), Nanotechnology in Medical Applications
[2] Compound annual growth rate CAGR based on USD figures (i.e. does not incorporate change in EUR/USD currency exchange rate)
[3] Estimate for 2012, forecast for 2020, CAGR for 2012-2020. Global View Research Inc.: http://www.grandviewresearch.com/industry-analysis/healthcare-nanotechology
[4] Frost & Sullivan, work undertaken for the NanoData project
[5] Forecast for 2020. Global View Research Inc.: http://www.grandviewresearch.com/industry-analysis/healthcare-nanotechology
[6] Estimate for 2013, VDI for BMBF https://www.bmbf.de/pub/nanoDE_Report_2013_englisch_bf.pdf